GSB Wealth Management LLC Sells 3,076 Shares of Becton, Dickinson and Company (NYSE:BDX)

GSB Wealth Management LLC trimmed its position in Becton, Dickinson and Company (NYSE:BDX) by 38.1% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 4,999 shares of the medical instruments supplier’s stock after selling 3,076 shares during the period. GSB Wealth Management LLC’s holdings in Becton, Dickinson and Company were worth $1,205,000 at the end of the most recent reporting period.

Other hedge funds have also recently made changes to their positions in the company. Livelsberger Financial Advisory purchased a new stake in shares of Becton, Dickinson and Company in the third quarter worth $26,000. Sound Income Strategies LLC increased its stake in Becton, Dickinson and Company by 35.8% in the 3rd quarter. Sound Income Strategies LLC now owns 167 shares of the medical instruments supplier’s stock worth $40,000 after acquiring an additional 44 shares during the last quarter. Opal Wealth Advisors LLC purchased a new stake in shares of Becton, Dickinson and Company in the 2nd quarter valued at about $45,000. Abound Wealth Management boosted its position in shares of Becton, Dickinson and Company by 96.0% during the 2nd quarter. Abound Wealth Management now owns 196 shares of the medical instruments supplier’s stock valued at $46,000 after acquiring an additional 96 shares during the last quarter. Finally, Chilton Capital Management LLC grew its holdings in shares of Becton, Dickinson and Company by 1,233.3% during the second quarter. Chilton Capital Management LLC now owns 200 shares of the medical instruments supplier’s stock worth $47,000 after purchasing an additional 185 shares in the last quarter. 86.97% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on BDX shares. Evercore ISI upped their price objective on Becton, Dickinson and Company from $286.00 to $290.00 and gave the stock an “outperform” rating in a report on Tuesday, October 1st. StockNews.com upgraded shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research report on Thursday, August 8th. Citigroup upgraded shares of Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and boosted their price objective for the stock from $255.00 to $275.00 in a report on Tuesday, October 1st. Raymond James reduced their target price on shares of Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating on the stock in a report on Friday, August 2nd. Finally, Stifel Nicolaus upped their target price on Becton, Dickinson and Company from $270.00 to $280.00 and gave the company a “buy” rating in a report on Friday, July 26th. Nine investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $282.63.

Becton, Dickinson and Company Stock Performance

Shares of NYSE BDX opened at $237.51 on Wednesday. The firm’s 50-day moving average price is $237.58 and its 200-day moving average price is $235.04. Becton, Dickinson and Company has a 52-week low of $218.75 and a 52-week high of $259.92. The company has a market cap of $68.64 billion, a PE ratio of 52.31, a PEG ratio of 1.79 and a beta of 0.42. The company has a quick ratio of 1.36, a current ratio of 1.85 and a debt-to-equity ratio of 0.70.

Becton, Dickinson and Company (NYSE:BDX) last announced its earnings results on Thursday, August 1st. The medical instruments supplier reported $3.50 earnings per share for the quarter, beating analysts’ consensus estimates of $3.31 by $0.19. The business had revenue of $4.99 billion during the quarter, compared to analyst estimates of $5.08 billion. Becton, Dickinson and Company had a net margin of 7.13% and a return on equity of 14.49%. The company’s quarterly revenue was up 2.3% compared to the same quarter last year. During the same period in the previous year, the business earned $2.96 EPS. As a group, analysts anticipate that Becton, Dickinson and Company will post 13.11 EPS for the current year.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.